Vermillion Inc. (VRML) Short Interest Update
Vermillion Inc. (NASDAQ:VRML) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 202,005 shares, a drop of 60.4% from the August 31st total of 510,215 shares. Based on an average trading volume of 27,996 shares, the days-to-cover ratio is presently 7.2 days. Currently, 0.6% of the shares of the stock are short sold.
Shares of Vermillion (NASDAQ:VRML) opened at 1.24 on Wednesday. The firm’s market cap is $64.76 million. Vermillion has a 12-month low of $0.92 and a 12-month high of $2.20. The firm has a 50-day moving average price of $1.33 and a 200-day moving average price of $1.30.
Vermillion (NASDAQ:VRML) last announced its earnings results on Wednesday, August 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. Vermillion had a negative return on equity of 121.09% and a negative net margin of 985.56%. On average, equities research analysts expect that Vermillion will post ($0.29) earnings per share for the current fiscal year.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Stock Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related stocks with our FREE daily email newsletter.